ReproCELL Incorporated (4978) Q1 2027 earnings summary

Executive summary

• Net sales for the three months ended June 30, 2026, rose 14.9% year-over-year to ¥546 million, with operating loss at ¥310 million and ordinary loss at ¥149 million, both improving from the prior year.

• Loss attributable to owners of parent was ¥149 million, a significant improvement from ¥304 million in the same period last year.

• The company operates two main segments: Research Support Business (short- to medium-term earnings) and Medical Business (medium- to long-term growth), both leveraging iPS cell technology.

Financial highlights

• Gross profit increased to ¥245 million from ¥194 million year-over-year.

• Research Support Business net sales grew 10.3% to ¥483 million, with segment profit of ¥20 million versus a loss last year.

• Medical Business net sales surged 69.2% to ¥63 million, with segment loss narrowing to ¥13 million from ¥58 million.

• Basic earnings per share improved to ¥(1.56) from ¥(3.21) year-over-year.

Outlook and guidance

• Full-year forecast for FY ending March 31, 2027, remains unchanged: net sales of ¥2,629 million (+17.7% YoY), operating loss of ¥630 million, and loss attributable to owners of parent of ¥458 million.

• No dividend is planned for the fiscal year.